NASDAQ:ENGN

enGene (ENGN) Stock Price, News & Analysis

enGene logo
$1.74 -0.02 (-0.85%)
As of 01:27 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About enGene Stock (NASDAQ:ENGN)

Advanced

Key Stats

Today's Range
$1.73
▼
$1.80
50-Day Range
$1.45
▼
$2.41
52-Week Range
$1.40
▼
$12.25
Volume
239,382 shs
Average Volume
1.05 million shs
Market Capitalization
$116.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.75
Consensus Rating
Moderate Buy

Company Overview

enGene is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

enGene Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

ENGN MarketRank™: 
4.038144895715 of 5 stars

enGene scored higher than 81% of companies evaluated by MarketBeat, and ranked 66th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    enGene has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 7 buy ratings, 4 hold ratings, and 2 sell ratings.

  • Upside Potential

    enGene has a consensus price target of $10.75, representing about 513.2% upside from its current price of $1.75.

  • Amount of Analyst Coverage

    enGene has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about enGene's stock forecast and price target.
  • Earnings Growth

    Earnings for enGene are expected to grow in the coming year, from ($1.82) to ($1.63) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of enGene is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of enGene is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    enGene has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about enGene's valuation and earnings.
  • Percentage of Shares Shorted

    2.71% of the float of enGene has been sold short.
  • Short Interest Ratio / Days to Cover

    enGene has a short interest ratio ("days to cover") of 1.92, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in enGene has recently increased by 8.08%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    enGene does not currently pay a dividend.

  • Dividend Growth

    enGene does not have a long track record of dividend growth.

  • News Sentiment

    enGene has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for enGene this week, compared to 8 articles on an average week.
  • Search Interest

    Only 1 people have searched for ENGN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added enGene to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $10,051.00 in company stock, which represents 0.0086% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, enGene insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,051.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    10.50% of the stock of enGene is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    64.16% of the stock of enGene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about enGene's insider trading history.
Receive ENGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for enGene and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ENGN Stock News Headlines

A free stock pick, from me to you
Elon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.tc pixel
enGene (NASDAQ:ENGN) Upgraded at Leerink Partners
enGene (NASDAQ:ENGN) Raised to "Overweight" at Wells Fargo & Company
Piper Sandler Upgrades enGene (NASDAQ:ENGN) to "Overweight"
See More Headlines

ENGN Stock Analysis - Frequently Asked Questions

enGene's stock was trading at $9.03 on January 1st, 2026. Since then, ENGN stock has decreased by 80.6% and is now trading at $1.7530.

enGene Holdings Inc. (NASDAQ:ENGN) released its quarterly earnings results on Tuesday, September, 8th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.04.

Shares of ENGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
9/08/2026
Today
11/20/2026
Next Earnings (Estimated)
12/22/2026
Fiscal Year End
10/31/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ENGN
Previous Symbol
NASDAQ:ENGN
CIK
1980845
Fax
N/A
Employees
82
Year Founded
1999

Price Target and Rating

High Price Target
$30.00
Low Price Target
$2.00
Potential Upside/Downside
+516.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$117.30 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-55.79%
Return on Assets
-45.17%

Debt

Debt-to-Equity Ratio
0.11
Current Ratio
10.21
Quick Ratio
10.21

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.60 per share
Price / Book
0.67

Miscellaneous

Outstanding Shares
67,020,000
Free Float
59,979,000
Market Cap
$116.95 million
Optionable
Optionable
Beta
-0.24

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:ENGN) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners